Ipilimumab and Gemcitabine for Advanced Pancreas Cancer: A Phase Ib Study.

Trial Profile

Ipilimumab and Gemcitabine for Advanced Pancreas Cancer: A Phase Ib Study.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2016 Results (n=16) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 21 Mar 2016 Planned number of patients changed from 28 to 21, according to ClinicalTrials.gov record.
    • 21 Mar 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top